Chris Neumann

Chris Neumann, PhD is a Sr. Director in the Pfizer Oncology Research Unit and Head of ADC Chemistry. Chris joined Seattle Genetics in 2012 where his research has focused primarily on the development on novel payloads for ADCs, including natural product derived cytotoxics, immune agonists and targeted protein degraders. Currently, his group is responsible for advancing next-gen payload and linker designs to clinical application. Prior to his industrial position, Chris obtained his PhD in Chemistry from Harvard University in the area of chemical genetics and completed postdoctoral work at Harvard Medical School in natural product enzymology.